Nuvation Bio
18 articles with Nuvation Bio
-
Nuvation Bio Reports First Quarter 2022 Financial Results and Provides Business Update
5/9/2022
Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial results for the first quarter ended March 31, 2022, and provided a business update.
-
Nuvation Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
2/28/2022
Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided a business update.
-
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-868 for the Treatment of Advanced Solid Tumors
1/20/2022
Nuvation Bio Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to evaluate NUV-868.
-
Nuvation Bio Provides Corporate Update and Highlights Key 2022 Milestones
1/10/2022
Nuvation Bio Inc. provided a corporate update and highlighted key 2022 milestones in anticipation of its presentation at the 40th Annual J.P. Morgan Healthcare Conference being held virtually January 10 – 13, 2022.
-
Omega raised $650 million, which it plans to invest in life science companies in the U.S. and Europe.
-
Nuvation Bio Receives FDA Fast Track Designation for NUV-422 for the Treatment of High-Grade Gliomas, Including Glioblastoma Multiforme
12/15/2021
Nuvation Bio Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to NUV-422, a cyclin-dependent kinase (CDK) 2/4/6 inhibitor, for the treatment of patients with high-grade gliomas, including glioblastoma multiforme.
-
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-422 for the Treatment of Prostate Cancer
12/13/2021
Nuvation Bio Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to evaluate NUV-422, a cyclin-dependent kinase (CDK) 2/4/6 inhibitor, for the treatment of prostate cancer.
-
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-422 for the Treatment of Advanced Breast Cancer
12/8/2021
Nuvation Bio Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to evaluate NUV-422, a yclin-dependent kinase (CDK) 2/4/6 inhibitor, for the treatment of advanced breast cancer.
-
Nuvation Bio Reports Third Quarter 2021 Financial Results and Provides Business Update
11/10/2021
Nuvation Bio Inc. today reported financial results for the third quarter ended September 30, 2021, and provided a business update.
-
Nuvation Bio Reports Second Quarter 2021 Financial Results and Provides Business Update
8/12/2021
Nuvation Bio Inc., a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, reported financial results for the second quarter ended June 30, 2021, and provided a business update.
-
BioSpace Movers & Shakers, June 4
6/4/2021
Biopharma and life sciences organizations strengthen their leadership teams and board with these Movers & Shakers. -
Nuvation Bio Appoints David C. Hanley, Ph.D., as Chief Technical Operations Officer
6/1/2021
Experienced technical operations and CMC leader brings scientific and strategic expertise in oncology drug development and life cycle management
-
Nuvation Bio to Participate in the Jefferies Virtual Healthcare Conference - May 26, 2021
5/26/2021
Nuvation Bio Inc., a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, announced that David Hung, M.D., founder and chief executive officer of Nuvation Bio, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021, at 9:00 a.m. ET.
-
Nuvation Bio Reports First Quarter 2021 Financial Results and Provides Business Update
5/17/2021
Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial results for the first quarter ended March 31, 2021, and provided a business update.
-
Nuvation Bio Granted Orphan Drug Designation for NUV-422 for the Treatment of Patients with Malignant Gliomas
3/11/2021
Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to NUV-422, a cyclin-dependent kinase (CDK) 2/4/6 inhibitor,
-
Nuvation Bio Closes Transaction with Panacea, Debuts as Publicly Traded Oncology Company
2/10/2021
Combined company renamed Nuvation Bio Inc., will be listed on the New York Stock Exchange under ticker symbol "NUVB" Strong cash position of approximately $830 million includes approximately $646 million held in Panacea's trust account and from concurrent private financings NEW YORK , Feb. 10, 2021 /PRNewswire/ -- Nuvation Bio I
-
Nuvation Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference
1/8/2021
Nuvation Bio Inc. , a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that David Hung , M.D., founder, president and chief executive officer, will present virtually at the 39 th Annual J.P. Morgan Healthcare Conference on Jan
-
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life science startups in North America that recently launched.